VAXART, INC revenue breakdown overview

VAXART, INC revenue for the last year amounted to 125.33 M MXN, the most of which — 125.33 M MXN — came from its highest performing source at the moment, Oral Recombinant Protein Vaccines, the year earlier bringing 2.09 M MXN. The greatest contribution to the revenue figure was made by United States — last year it brought VAXART, INC 125.33 M MXN, and the year before that — 2.09 M MXN.